drugset
drugset / Trial / NCT06716164

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

NCT06716164 ↗

Phase 0 Recruiting 36 enrolled Zhejiang University Leman Biotech Co., Ltd. · collab
NaSequentialOpen-labelTreatment

Summary

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Non-Hodgkin lymphoma

Timeline

Start
2024-12-01
Primary completion
2026-12-01
Completion
2027-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Metabolically Armed CD19 CAR-T cells Cell therapy — Intravenous

Indications

B-cell non-Hodgkin lymphoma